SPK-9001
Author: Daniel Chancellor
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
SPK-9001 is Spark Therapeutics’ leading candidate in development for hemophilia B. Like SPK-8011, SPK-9001 is also an adeno-associated virus-mediated gene therapy, but instead delivers factor IX (fIX). Specifically, SPK-9001 encodes the Padua variant of fIX, which has eightfold greater clotting activity than the normal protein.
In December 2014, Pfizer signed an exclusive deal with Spark Therapeutics to collaborate on the development of SPK-9001. Pfizer will assume full clinical responsibility and commercialization rights should the drug progress to Phase III, which is expected to occur during 2018.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 SPK-9001 : Hemophilia
LIST OF FIGURES
8 Figure 1: SPK-9001 for hemophilia – SWOT analysis
LIST OF TABLES
6 Table 1: SPK-9001 drug profile
7 Table 2: SPK-9001 Phase I/II data in hemophilia
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Kovaltry 
Sign up to the